---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-268404"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:23:27.637836+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RMC-6236 shows 38% ORR in NSCLC, 27-36% in PDAC; median PFS 9.8 mo and 8.5-8.8 mo

## Summary
- NSCLC efficacy: ORR 38% (15/40), median PFS 9.8 mo, median OS 17.7 mo in RAS G12X pts (cutoff Sept 30, 2024).
- PDAC 2L: ORR 36% (G12X) and 27% (broader RAS); median PFS 8.8 and 8.5 mo; 6-mo OS 100% and 97% (cutoff Jul 23, 2024).
- PDAC safety at 300 mg: 34% Grade ≥3 TRAEs, no Grade 5; median duration 5.2 mo, mean dose intensity 89%.
- NSCLC safety: Grade ≥3 TRAEs 27% overall, 41% at 300 mg; one Grade 4 pneumonitis at 300 mg; median duration 5.5 mo (120-220 mg).
- Combination RMC-6236+RMC-6291 in KRAS G12Ci-experienced CRC: ORR 25% (3/12), DCR 92%; plans for Phase 3 NSCLC trial vs docetaxel.

## SEC filing metadata
- accession: 0001193125-24-268404
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312524268404/0001193125-24-268404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312524268404/d169582d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-268404
- JSON: https://secwatch.observer/filing/0001193125-24-268404.json
- Plain text: https://secwatch.observer/filing/0001193125-24-268404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.